Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VGX-3400 · 1 trial · 1 indication
Frequency, severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
| Arm | Type | Description |
|---|---|---|
| 0.6mg DNA/dose | EXPERIMENTAL | Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1 |
| 2mg DNA/dose | EXPERIMENTAL | Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1 |
| 6mg DNA/dose | EXPERIMENTAL | Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1 |
| Name | Type | Description |
|---|---|---|
| VGX-3400 | BIOLOGICAL | Plasmid DNA delivered via IM injection with electroporation |
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI) * Male subjects 20-39 years of age * Healthy subjects as judged by the Investigator based on...
VGX-3400 is an investigational monoclonal antibody being studied for use in healthy adults. It was evaluated in a Phase 1 clinical trial as a preventive measure against H5N1 avian flu virus. The study enrolled healthy adult males in South Korea to assess the safety and immune response of the vaccine.
VGX-3400 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol INO. The company conducted a Phase 1 clinical trial of VGX-3400 in healthy adult males in South Korea.
VGX-3400 is in Phase 1 clinical development. It has completed a Phase 1 trial (NCT01184976) that evaluated the drug in healthy adult males. The drug is investigational and has not been approved by regulatory authorities for commercial use.
VGX-3400 has one completed clinical trial, NCT01184976, titled "Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males." This Phase 1 study enrolled 30 healthy adult males in South Korea and was completed.
VGX-3400 is a monoclonal antibody designed to target the H5N1 avian flu virus. It is being developed as a preventive vaccine against this strain of influenza. The drug was studied in a Phase 1 trial to evaluate its safety and immunogenicity in healthy adults.